celecoxib has been researched along with Sarcoma, Ewing in 5 studies
Sarcoma, Ewing: A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma." | 7.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| "Previously, we reported that celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, prevented lung metastases but did not affect tumor growth in a model of Ewing sarcoma." | 3.78 | Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma. ( Barlow, M; Edelman, M; Glick, RD; Soffer, SZ; Steinberg, BM, 2012) |
| "Celecoxib prevents lung metastasis in a murine model of Ewing sarcoma with no effect on tumor size or neovascularization." | 3.77 | Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma. ( Edelman, M; Gendy, AS; Glick, RD; Lipskar, A; Soffer, SZ; Steinberg, BM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pramanik, R | 1 |
| Agarwala, S | 1 |
| Gupta, YK | 1 |
| Thulkar, S | 1 |
| Vishnubhatla, S | 1 |
| Batra, A | 1 |
| Dhawan, D | 1 |
| Bakhshi, S | 1 |
| Behr, CA | 1 |
| Hesketh, AJ | 1 |
| Barlow, M | 2 |
| Glick, RD | 3 |
| Symons, M | 1 |
| Steinberg, BM | 3 |
| Soffer, SZ | 3 |
| Gendy, AS | 1 |
| Lipskar, A | 1 |
| Edelman, M | 2 |
| Felgenhauer, JL | 1 |
| Nieder, ML | 1 |
| Krailo, MD | 1 |
| Bernstein, ML | 1 |
| Henry, DW | 1 |
| Malkin, D | 1 |
| Baruchel, S | 1 |
| Chuba, PJ | 1 |
| Sailer, SL | 1 |
| Brown, K | 1 |
| Ranganathan, S | 1 |
| Marina, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study[NCT01858571] | Phase 3 | 108 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| A Pilot Study of Low-Dose Antiangiogenic Chemotherapy in Combination With Standard Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Family of Tumors[NCT00061893] | Phase 2 | 38 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00061893)
Timeframe: 24 months after start of protocol therapy
| Intervention | percentage of participants (Number) |
|---|---|
| Combination Chemotherapy | 35 |
An incidence of severe toxicity is defined to be the occurrence of grade 3 or higher infection or grade 3 or higher sensory neuropathy during cycles 1-2 of protocol therapy. If 12 or more patients experience grade 3 or higher infection or five or more patients experience grade 3 or higher sensory neuropathy during cycles 1-2 of protocol therapy, the regimen will be flagged as being associated with an excessive rate of severe toxicity. (NCT00061893)
Timeframe: The first two cycles (6 weeks) of protocol chemotherapy
| Intervention | participants (Number) | |
|---|---|---|
| Grade 3 or Higher Infection | Grade 3 or Higher Sensory Neuropathy | |
| Combination Chemotherapy | 1 | 1 |
2 trials available for celecoxib and Sarcoma, Ewing
| Article | Year |
|---|---|
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy P | 2017 |
A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chil | 2013 |
3 other studies available for celecoxib and Sarcoma, Ewing
| Article | Year |
|---|---|
Celecoxib inhibits Ewing sarcoma cell migration via actin modulation.
Topics: Actin Cytoskeleton; Actins; beta Catenin; Caco-2 Cells; Celecoxib; Cell Movement; Cyclooxygenase 2 I | 2015 |
Selective inhibition of cyclooxygenase-2 suppresses metastatic disease without affecting primary tumor growth in a murine model of Ewing sarcoma.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 In | 2011 |
Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.
Topics: Basement Membrane; Bone Neoplasms; Celecoxib; Cell Line, Tumor; Cell Movement; Cyclooxygenase 2; Cyc | 2012 |